Steven Nissen, MD, and Luke Laffin, MD, discuss late-breaking data from the Phase II KARDINAL Trial evaluating Tonlamarsen, a once-monthly therapeutic for uncontrolled multidrug therapy. They review study design, blood pressure outcomes and the potential clinical role of long-acting injectable therapies to address adherence gaps in real-world hypertension management.
View current clinical trials. https://my.clevelandclinic.org/departments/heart/clinical-trials
Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.
Cardiac Consult: A Cleveland Clinic Podcast for Healthcare Professionals